IDM Pharma, Inc., a biopharmaceutical company, engages in the development of products that activate the immune system to treat and control cancer. It is developing two types of products designed to destroy cancer cells by activating innate immunity and prevent tumor recurrence by triggering a specific adaptive immune response. The company has five products in clinical development. Its lead product candidate, Junovan, has completed a Phase III clinical trial for the treatment of osteosarcoma, a bone cancer. IDM Pharma’s three products are in Phase II clinical trials, which include Bexidem for the treatment of bladder cancer, Uvidem for the treatment of melanoma, and EP-2101 for the...